

Date and time: Tuesday 7 October 2014, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting **Diagnosis and monitoring of asthma**
13

Place: **Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ**

Present: John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric
Respiratory Medicine
Val Hudson, Patient member
Angela Key, Chief Respiratory Physiologist
Matthew Masoli, Consultant Respiratory Physician
Andrew Menzies-Gow (Chair), Consultant in Respiratory Medicine
Tahmina Siddiqui, General Practitioner partner
Michael Thomas, Professor of Primary Care Research & Principal in
General Practice (MT did not formally participate for the discussion on
FeNO in items 3, 4, 5, 7 or 8)
Emily Davies, Senior Research Fellow, NCGC
Elisabetta Fenu, Senior Health Economist, NCGC (item 5 onwards)
Alex Haines, Health Economist, NCGC
Bernard Higgins, Clinical Director, NCGC
Emma Madden, Research Fellow, NCGC
Amelia Unsworth, Project Manager, NCGC
Giulia Zuodar, Document Editor/Process Assistant, NCGC (notes)

Apologies: Tara Burn, Patient member
Jill Cobb, Information Scientist, NCGC
Ren Gilmartin, Respiratory Nurse Specialist
Gareth Haman, Senior Medical Editor, NICE
Melanie McFeeters, Consultant Nurse in Children’s Respiratory
Diseases
Georgina Russell, RCP Clinical Fellow (Specialist Trainee Adviser)

In attendance:

NICE Staff: NICE attendee 1	Caroline Keir , Guideline Commissioning Manager	
NICE attendee 2	Julie Royce, Associate Director - Implementation Support (items 8 & 9 only)	

Observers:

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the thirteenth meeting of this GDG. Apologies were received from TB, RG, GH, MMF and GR.

The Chair reviewed and requested updates to the declarations of interest register. AMG declared that he received lecture fees for a presentation on severe asthma for Boehringer Ingelheim, lecture fees for a pro con debate on severe asthma for Novartis, and lecture fees for a presentation on treatment options for severe asthma and a severe asthma workshop for Boehringer-Ingelheim. These DOIs were classified as non-specific personal pecuniary interests. The guideline lead agreed that no action was required. No other new declarations of interest were received and therefore no action was required.

2. **GDG12 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Review changes to draft LETRs**

The GDG reviewed the draft 'recommendations and link to evidence'.

4. **Review changes to draft research recommendations**

The GDG reviewed the draft research recommendations.

5. **Re-runs: Evidence review: FeNO for monitoring**

The GDG reviewed the updated evidence review on FeNO for monitoring.

6. **Update: HE model**

The GDG was given a presentation on the HE model update.

7. **Diagnostic algorithms & draft recommendations**

The GDG reviewed the draft algorithms and draft recommendations.

8. **Agree key priorities for implementation**

The GDG agreed the key priorities for implementation.

9. **Plans for implementation**

The GDG was given a presentation on the plans for implementation.

10. **Any other business**

None.

Date, time and venue of the next meeting

Monday 30 March 2015, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ.